SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare ...

Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Disease control and reduced glucocorticoid doses ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Investigational crinecerfont reduced the need for ...

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data ...

Please provide your email address to receive an email when new articles are posted on . Crinecerfont, an oral nonsteroidal treatment, reduced mean daily glucocorticoid dose vs. placebo for people with ...

Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...

New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal Hyperplasia CAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid Dosing Phase ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to ...

CAHmelia-203 Topline Results Anticipated in the First Quarter of 2024 CAHmelia-204 Completion of Enrollment Anticipated in Early First Quarter of 2024 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ...